HG-7-85-01

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

HG-7-85-01 

HG-7-85-01 是一种 Bcr-AblPDGFRαKitSrc 激酶的野生型和看门突变形式的 II 型 ATP 竞争性抑制剂。HG-7-85-01 抑制 T315I 突变型 Bcr-Abl (T315I mutant Bcr-Abl) 激酶,KDRRETIC50 为 3 nM,20 nM 和 30 nM,对其他激酶的抑制作用很小或没有抑制作用 (IC50>2 μM)。HG-7-85-01 通过诱导细胞凋亡 (apoptosis) 和抑制细胞周期进程来抑制细胞增殖。

HG-7-85-01

HG-7-85-01 Chemical Structure

CAS No. : 1258391-13-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression[1].

IC50 & Target

Bcr-AblT315I

3 nM (IC50)

PDGFRα

440 nM (IC50)

JAK1

120 nM (IC50)

KDR

20 nM (IC50)

RET

30 nM (IC50)

MK5

560 nM (IC50)

体外研究
(In Vitro)

HG-7-85-01 (0-1 μM; 24 hours; BCR-ABL-, BCR-ABL-T315I-, Kit-T670I-, PDGFRα-T674M-, and PDGFRα-T674I-expressing cells) treatment leads to G0G1 arrest of BCR-ABL-expressing cells[1].
HG-7-85-01 (0-1 μM; 72 hours; BCR-ABL-, BCR-ABL-T315I-, Kit-T670I-, PDGFRα-T674M-, and PDGFRα-T674I-expressing cells) treatment also leads to induction of apoptosis of BCR-ABL-expressing cells[1].
HG-7-85-01 treatment potently and selectively inhibits the proliferation of 32D- and Ba/F3 cells expressing nonmutant BCR-ABL and the BCR-ABL-T315I gatekeeper mutant. HG-7-85-01 shows higher potency against nonmutant BCR-ABL and BCR-ABL-T315I (IC50 = 0.06-0.14 μM)[1].
HG-7-85-01 inhibits BCR-ABL kinase activity in a concentration-dependent manner, suggesting selective targeting of the BCR-ABL kinase as the mechanism of action of HG-7-85-01[1].
HG-7-85-01 potently inhibits the proliferation of Ba/F3 cells expressing the Kit-T670I gatekeeper mutation (Ba/F3- Kit-T670I) and Ba/F3 cells expressing TEL/PDGFRβ and no effect on parental Ba/F3 cells. HG-7-85-01 inhibits Kit, PDGFR phosphorylation in a concentration-dependent manner[1].
The PDGFRα-T674M and PDGFRα-T674I gatekeeper mutant variants are highly responsive to HG-7-85-01 and significant IL-3 rescue[1].
HG-7-85-01 inhibits the proliferation of Ba/F3 cells transformed with human c-Src (EC50 = 190 nM), T338I Src (EC50 = 290 nM), and T338M Src (EC50 = 150 nM; chicken c-Src numbering). And potently inhibits the proliferation of exon 11 Kit mutant-expressing cells, exon 9 kit mutant-expressing cells are significantly less responsive[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: BCR-ABL-, BCR-ABL-T315I-, Kit-T670I-, PDGFRα-T674M-, and PDGFRα-T674I-expressing cells
Concentration: 0 μM, 0.01 μM, 0.1 μM and 1 μM
Incubation Time: 24 hours
Result: Led to G0G1 arrest of BCR-ABL-expressing cells.

Apoptosis Analysis[1]

Cell Line: BCR-ABL-, BCR-ABL-T315I-, Kit-T670I-, PDGFRα-T674M-, and PDGFRα-T674I-expressing cells
Concentration: 0 μM, 0.01 μM, 0.1 μM and 1 μM
Incubation Time: 72 hours
Result: Led to induction of apoptosis of BCR-ABL-expressing cells.

体内研究
(In Vivo)

HG-7-85-01 has limited oral bioavailability (BAV % F mouse = 5 %, rat = 19 %), a moderate half life (T1/2 mouse =1.1 h rat = 5.8 hours), a relative low maximal serum concentration (Cmax mouse = 106 ng/mL at 10 mg/kg , rat = 292 ng/mL and 2 mg/kg ) and a relatively high clearance (Cl mouse = 23 ml/min/kg, rat = 13 ml/min/kg) [1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

608.68

Formula

C31H31F3N6O2S

CAS 号

1258391-13-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Ellen Weisberg, et al. Discovery of a Small-Molecule Type II Inhibitor of Wild-Type and Gatekeeper Mutants of BCR-ABL, PDGFRalpha, Kit, and Src Kinases: Novel Type II Inhibitor of Gatekeeper Mutants. Blood. 2010 May 27;115(21):4206-16.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务